211 related articles for article (PubMed ID: 35877212)
1. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S; Fung AS; Perdrizet KA; Chen K; Li JJN; Le LW; Cabanero M; Karsaneh OAA; Tsao MS; Morganstein J; Ranich L; Smith AC; Wei C; Cheung C; Shepherd FA; Liu G; Bradbury P; Pal P; Schwock J; Sacher AG; Law JH; Stockley TL; Leighl NB
Curr Oncol; 2022 Jun; 29(7):4428-4437. PubMed ID: 35877212
[TBL] [Abstract][Full Text] [Related]
2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
5. Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W
Intern Med J; 2024 Apr; 54(4):596-601. PubMed ID: 37713593
[TBL] [Abstract][Full Text] [Related]
6. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
[TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract][Full Text] [Related]
8. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
10. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
[TBL] [Abstract][Full Text] [Related]
12. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
14. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
19. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Campanella NC; Silva EC; Dix G; de Lima Vazquez F; Escremim de Paula F; Berardinelli GN; Balancin M; Chammas R; Mendoza Lopez RV; Silveira HCS; Capelozzi VL; Reis RM
Pathobiology; 2020; 87(3):208-216. PubMed ID: 32369821
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
